Somewhat Positive News Coverage Somewhat Unlikely to Impact Alere (NYSE:ALR) Share Price
Media headlines about Alere (NYSE:ALR) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alere earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.3782955908195 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Alere (ALR) Says Immunalysis Receives FDA Clearance for SEFRIA … – StreetInsider.com (streetinsider.com)
- Immunalysis Receives FDA Clearance for SEFRIA™ Fentanyl Urine Drug Screening Test (finance.yahoo.com)
- Alere Inc. (NYSE:ALR) Scheduled to Post Quarterly Earnings on Monday (americanbankingnews.com)
- Weekly Performance of Healthcare stock: Alere Inc. (ALR) stock fluctuated 0.12% higher – Street Observer (press release) (streetobserver.com)
- Alere Inc. (NYSE:ALR) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
Shares of Alere (NYSE:ALR) traded down 0.28% during midday trading on Monday, reaching $50.39. 955,422 shares of the company traded hands. The firm’s market capitalization is $4.40 billion. Alere has a 12 month low of $34.41 and a 12 month high of $50.63. The company has a 50 day moving average of $50.27 and a 200 day moving average of $44.70.
A number of brokerages have recently weighed in on ALR. BidaskClub lowered shares of Alere from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Zacks Investment Research upgraded shares of Alere from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. BTIG Research restated a “hold” rating on shares of Alere in a report on Wednesday, May 24th. Canaccord Genuity lowered shares of Alere from a “buy” rating to a “hold” rating and set a $51.00 price objective on the stock. in a report on Tuesday, June 6th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $51.00 price objective on shares of Alere in a report on Thursday, June 1st. Seven equities research analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and a consensus price target of $48.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Alere (NYSE:ALR) Share Price” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/07/31/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-alere-nysealr-share-price.html.
Alere Company Profile
Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.
Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with MarketBeat.com's FREE daily email newsletter.